Point72 (Difc) LTD Candel Therapeutics, Inc. Transaction History

Point72 (Difc) LTD

$2.64 Trillion
Q2 2025

A detailed history of Point72 (Difc) LTD transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Point72 (Difc) LTD holds 146 shares of CADL stock, worth $807. This represents 0.0% of its overall portfolio holdings.

Number of Shares

146

Holding current value

$807

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2025 Aug 14, 2025	BUY	$4.39 - $6.04 $640 - $881	146 New	146 $740,000
Q2 2024 Aug 14, 2024	BUY	$1.68 - $14.0 $8,277 - $68,978	4,927 New	4,927 $30.5 Million

Others Institutions Holding CADL

# of Institutions

Shares Held

15.3M

Call Options Held

570K

Put Options Held

203K

Acorn Capital Advisors, LLC New York, NY

2.58M
Shares

$14.3 Million
8.54% of portfolio
Northpond Ventures, LLC

1.94M
Shares

$10.7 Million
48.35% of portfolio
Vanguard Group Inc Valley Forge, PA

1.79M
Shares

$9.89 Million
0.0% of portfolio
Portolan Capital Management, LLC Boston, MA

1.62M
Shares

$8.97 Million
0.59% of portfolio
Geode Capital Management, LLC Boston, MA

904K
Shares

$5 Million
0.0% of portfolio

View Full List

About Candel Therapeutics, Inc.

Ticker CADL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,891,900
Market Cap $160M
Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...

More about CADL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 (Difc) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 (Difc) LTD with notifications on news.

Account